TFPI2 Antikörper (AA 100-235)

Produktnummer ABIN7869767

Dieser Maus Monoklonal Antikörper detektiert spezifisch TFPI2 in WB und IHC (p). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für TFPI2 Antikörper (AA 100-235) (ABIN7869767)

Target: TFPI2 (Tissue Factor Pathway Inhibitor 2 (TFPI2))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TFPI2 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: TFPI2-13027

Produktdetails anti-TFPI2 Antikörper

Bindungsspezifität: AA 100-235

Verwendungszweck: Tissue factor pathway inhibitor 2 Antibody / TFPI2

Aufreinigung: Protein G affinity

Immunogen: A portion of amino acids 100-235 from human TFPI2 protein was used as the immunogen for the Tissue factor pathway inhibitor 2 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Tissue factor pathway inhibitor 2 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the Tissue factor pathway inhibitor 2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu TFPI2

Target: TFPI2 (Tissue Factor Pathway Inhibitor 2 (TFPI2))

Andere Bezeichnung: Tissue factor pathway inhibitor 2

Hintergrund: The extrinsic pathway of blood coagulation is initiated by contact of plasma factor VII with tissue factor, a cellular membrane glycoprotein that normally is segregated from the bloodstream but can be exposed after tissue injury or newly synthesized in endothelial cells or leukocytes after stimulation by endotoxin and cytokines. Inhibition of Factor VIIa tissue factor activity requires a plasma component (tissue factor pathway inhibitor (TFPI), lipoprotein-associated coagulation inhibitor (LACI) or extrinsic pathway inhibitor (EPI)) and factor Xa. TFPI directly inhibits factor Xa, and, in an Xa-dependent fashion, also inhibits the Factor VIIa tissue factor catalytic complex. TFPI is a multivalent, Kunitz-type proteinase inhibitor that circulates in association with plasma lipoproteins VLDL, LDL, and HDL. TFPI-2 (also known as placental protein 5) is a related glycoprotein that was originally isolated from human placenta.

UniProt: P48307